THERAPEUTIC APHERESIS AND DIALYSIS is an esteemed journal published by Wiley, focusing on the fields of hematology and nephrology. Since its inception in 2003, the journal has provided a dedicated platform for research and advancements in therapeutic apheresis and dialysis methodologies, offering valuable insights for clinicians and researchers alike. With an ISSN of 1744-9979 and an E-ISSN of 1744-9987, the journal has established itself within Q3 in both the hematology and nephrology categories. Its Scopus rankings place it at #44 in nephrology and #79 in hematology, indicating its growing influence in these critical areas of medical research. Although it does not currently offer open access, THERAPEUTIC APHERESIS AND DIALYSIS remains a vital resource for professionals aiming to stay at the forefront of innovations and practices through 2024 and beyond. Researchers, healthcare professionals, and students are encouraged to engage with the latest findings and discussions presented within its pages, solidifying its role in enhancing patient care and therapeutic strategies.

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.